Anti-angiogenic drug scheduling optimisation with application to colorectal cancer

Bevacizumab (bvz) is a first choice anti-angiogenic drug in oncology and is primarily administered in combination with chemotherapy. It has been hypothesized that anti-angiogenic drugs enhance efficacy of cytotoxic drugs by “normalizing” abnormal tumor vessels and improving drug penetration. Neverth...

Descripción completa

Detalles Bibliográficos
Autores principales: Sturrock, M., Miller, I. S., Kang, G., Hannis Arba’ie, N., O’Farrell, A. C., Barat, A., Marston, G., Coletta, P. L., Byrne, A. T., Prehn, J. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6060139/
https://www.ncbi.nlm.nih.gov/pubmed/30046049
http://dx.doi.org/10.1038/s41598-018-29318-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6060139/
https://www.ncbi.nlm.nih.gov/pubmed/30046049
http://dx.doi.org/10.1038/s41598-018-29318-5

Ejemplares similares